X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: BioLineRx
Deal Size: $279.6 million Upfront Cash: $29.6 million
Deal Type: Licensing Agreement October 31, 2023
Details:
YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.
Lead Product(s): Zimberelimab
Therapeutic Area: Oncology Product Name: YuTuo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
Lead Product(s): Zimberelimab
Therapeutic Area: Oncology Product Name: GLS-010
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
